Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
July 8 () - Hong Kong-listed Sino Biopharmaceutical said on Wednesday ‌it has granted AstraZeneca ‌the rights to develop a drug ​de...
Neutral
0.0